The bridging function of hepatic lipase clears plasma cholesterol in LDL receptor-deficient “apoB-48-only” and “apoB-100-only” mice

Helén L. Dichek, Kun Qian, and Nalini Agrawal

Department of Pediatrics, University of Washington, Seattle, WA 98195

Abstract Hepatic lipase clears plasma cholesterol by lytic and nonlytic processing of lipoproteins. We hypothesized that the nonlytic processing (known as the bridging function) clears cholesterol by removing apoB-48 and apoB-100-containing lipoproteins by whole particle uptake. To test our hypotheses, we expressed catalytically inactive human HL (ciHL) in LDL receptor deficient “apoB-48-only” and “apoB-100-only” mice. Expression of ciHL in “apoB-48-only” mice reduced cholesterol by reducing LDL-C (by 54%, 46 ± 6 vs. 19 ± 8 mg/dl, P < 0.001). ApoB-48 was similarly reduced (by 60%). The similar reductions in LDL-C and apoB-48 indicate cholesterol removal by whole particle uptake. Expression of ciHL in “apoB-100-only” mice reduced cholesterol by reducing IDL-C (by 37%, 61 ± 19 vs. 58 ± 12 mg/dl, P < 0.003). Apo-B100 was also reduced (by 27%). The contribution of nutritional influences was examined with a high-fat diet challenge in the “apoB-100-only” background. On the high fat diet, ciHL reduced IDL-C (by 30%, 355 ± 72 vs. 257 ± 64 mg/dl, P < 0.04) but did not reduce apoB-100. The reduction in IDL-C in excess of apo-B100 suggests removal either by selective cholesteryl ester uptake, or by selective removal of larger, cholesteryl ester-enriched particles. Our results demonstrate that the bridging function removes apoB-48 and apoB-100-containing lipoproteins by whole particle uptake and other mechanisms.—Dichek, H. L., K. Qian, and N. Agrawal. The bridging function of hepatic lipase clears plasma cholesterol in LDL receptor-deficient “apoB-48-only” and “apoB-100-only” mice. J. Lipid Res. 2004. 45: 551–560.

Supplementary key words triglyceride • remnants • fast protein liquid chromatography • apolipoprotein A-I • apolipoprotein B • apolipoprotein E • low density lipoprotein

Human hepatic lipase (HL) is a central component of lipoprotein metabolism (1, 2). HL is synthesized and secreted by the liver, where it is anchored to the surface of hepatocytes and sinusoidal endothelial cells via heparan sulfate proteoglycans (HSPGs) (3–6). HL hydrolyzes triglycerides and phospholipids in remnants (chylomicron remnants and IDL) and LDL to yield particles that are depleted in triglycerides and phospholipids and are more optimal for receptor-mediated uptake (2, 7–9). HL may also play a role in reverse cholesterol transport by hydrolyzing phospholipids in HDL, which converts HDL2 to HDL3 (10, 11).

The significant role of HL in lipoprotein metabolism is apparent from human studies and data generated in animals. For example, plasma of HL-deficient patients contains high levels of apolipoprotein B (apoB)-containing lipoproteins and HDL (12–17). Infusion of anti-HL antibodies in rats and monkeys increases levels of apoB-containing lipoproteins and HDL (18–20). Expression of moderate and high levels of wild-type HL in mice and rabbits reduces levels of apoB-containing lipoproteins and HDL (6, 21–24). Taken together, these studies indicate a major role for HL in determining the plasma levels of apoB-containing lipoproteins and HDL.

HL regulates plasma levels of apoB-containing lipoproteins using both catalytic and bridging functions (6, 25). In particular, wild-type HL (reflecting both catalytic and bridging functions) reduces plasma levels of both apoB-48- and apoB-100-containing lipoproteins. However, the contribution of the bridging function to their reduction is not clear. Previous in vitro studies demonstrated roles for the bridging function in the cellular uptake of chyomicrons, remnants, and LDL. Cells transfected with wild-type HL and studied at 4°C to abolish catalytic activity showed enhanced uptake of human chyomicrons, and cells incubated in the presence of heat-inactivated HL displayed increased binding and uptake of remnants (26, 27). Cells transfected with a mutant, catalytically inactive hepatic li-

Abbreviations: apoB, apolipoprotein B; ciHL, catalytically inactive hepatic lipase; FPLC, fast-protein liquid chromatography; HDL-C, HDL-cholesterol; HL, hepatic lipase; HSPG, heparan sulfate proteoglycan; IDL-C, IDL-cholesterol; LDI-C, LDL-cholesterol; LDLR, LDL receptor; LRP, LDL receptor-related protein; SR-BI, scavenger receptor BI.

1 To whom correspondence should be addressed.

e-mail: hdichek@u.washington.edu
pase (ciHL) displayed more association with \(^{125}\)I-labeled LDL than did control transfected cells, thus suggesting that the bridging function facilitated LDL receptor (LDLR)-mediated uptake of LDL (26,28).

The effect of the bridging function on plasma levels of apoB-containing lipoproteins has also been studied in vivo in apoE-deficient and LDLR-deficient mice. In apoE-deficient mice (which have high levels of apoB-48-containing lipoproteins), overexpression of ciHL reduced levels of VLDL, remnants, and LDL (6,29). In LDLR-deficient mice (which have high levels of both apoB-48 and apoB-100-containing lipoproteins), overexpression of ciHL also reduced remnants and LDL (30). This latter finding indicated that the bridging function uses an LDLR-independent pathway to reduce apoB levels, inasmuch as both apoB-48- and apoB-100-containing lipoproteins are catabolized in part via the LDLR (which is absent in LDLR-deficient mice) (31).

On the basis of this information, we hypothesized that the bridging function of HL facilitates removal of both apoB-48 and apoB-100-containing lipoproteins. Furthermore, we hypothesized that the bridging function facilitates particle removal by whole-particle uptake. To test our hypotheses, we expressed ciHL in LDLR-deficient mice that were genetically modified to express only apoB-48 or apoB-100 and determined the effect of the bridging function on levels of apoB-100 and that no longer had the wild-type mouse apoB background had 81.25% C57Bl/6 and 18.75% SJL, and the Ldlr\(^{-/-}\)/apob\(^{100/100}\) background had 96% C57/Bl6, 1.5% SJL, and 1.5% ICR.

Liver-specific expression of the HLS145G transgene was conferred by sequences in the human apoE gene as described (6): 3 kb of the 5′-flanking sequence, the first exon, the first intron, and the first six untranslated nucleotides of the second exon, a poly linker for cDNA insertion, the nontranslated portion of the fourth exon, 0.1 kb of 3′-flanking sequence, and the first hepatic control region of the apoE locus.

Expression of the ciHL transgene was determined by polymerase chain reaction (PCR) analysis of tail DNA using the primers H-26 (5′-AGGCAATTTGGAAAGAGCCTAAGCTG3′) and H-36 (5′-GGAGCTCTTAACCTGTATGATAAA-CCTGTGA3′) in the following program: an initial 3 min denaturation at 92°C followed by 30 cycles of a 1 min denaturation at 92°C, a 2 min annealing at 60°C, and a 3 min elongation at 72°C, ending with a 2 min elongation at 72°C. This yielded a 987 bp fragment of the human HL transgene. Homozygosity for the hl\(^{-/-}\) background was determined by PCR of tail DNA using the primers hl-433 (5′-TTCCTGGACGA-AGATC-TGACCTAAATG-3′) and hl-508 (5′-CTGTTTGTTCTCTGGAATG-3′) in the following program: an initial 5 min denaturation at 92°C, followed by 30 cycles of a 1 min denaturation at 92°C, a 2 min annealing at 60°C, and a 3 min elongation at 72°C, ending with a 3 min elongation at 72°C. This yielded a 200 bp fragment of the mouse HL knockout gene and a 100 bp product of the wild-type mouse HL gene.

Homozygosity for the gene-targeted LDLR gene in Ldlr\(^{-/-}\)/apob\(^{100/100}\) mice was determined by PCR (33). Homozygosity for the apob\(^{100/100}\) and apob\(^{48/48}\) backgrounds was confirmed by PCR analysis of tail DNA (using a protocol developed by Dr. Stephen G. Young and colleagues) as follows; primers M49mus 5′-TGA-TAC-TGT-TCA-TCA-AGA-A-3′ and M50mus 5′-TGA-TAC-TGT-TCA-TCA-TGA-A-3′ (a gift from Dr. Stephen G. Young). Mice that were homozygous for the Ldlr\(^{-/-}\)/apob\(^{100/100}\) transgene had two bands: 281 bp and 181 bp, whereas mice that were homozygous for the Ldlr\(^{-/-}\)/apob\(^{48/48}\) transgene had one band, 100 bp, and the LDLR-deficient mice had no bands.

Genetically modified mice

Mice that were genetically modified to express only mouse apoB-100 (apob\(^{100/100}\)) (31) (a gift from Dr. Stephen G. Young, Gladstone Institute of Cardiovascular Disease, San Francisco, CA) were bred with Ldlr\(^{-/-}\)/apob\(^{100/100}\) mice (that have the wild-type mouse apoB gene), and the resulting offspring were bred with each other to yield LDLR-deficient mice that were homozygous for apoB-100 and that no longer had the wild-type mouse apoB gene. The resulting Ldlr\(^{-/-}\)/apob\(^{100/100}\) mice were bred with Ldlr\(^{-/-}\)/apob\(^{100/100}\) mice that are transgenic for a human ciHL (HLS145G). Also, LDLR-deficient mice that were genetically modified to express only mouse apoB-48 (Ldlr\(^{-/-}\)/apob\(^{48/48}\)) (31) (also a gift from Dr. Stephen G. Young) were bred with Ldlr\(^{-/-}\)/apob\(^{48/48}\) mice that are transgenic for human HL (Ldlr\(^{-/-}\)/apob\(^{48/48}\)HL\(^{S145G}\)). The resulting littersmates were bred to achieve homozygosity for both the genetically modified mouse apoB gene (to yield either Ldlr\(^{-/-}\)/apob\(^{48/48}\) or apob\(^{100/100}\)) and the gene-targeted mouse LDLR gene as well as heterozygosity for the ciHL transgene (30). The wild-type mouse apoB gene was absent in these mice. The ciHL transgene was generated previously and consists of a mutant human HL cDNA in which a glycine replaces serine at position 145 in the catalytic triad (HLS145G), resulting in expression of ciHL (6).

Ldlr\(^{-/-}\)/apob\(^{48/48}\)HL\(^{S145G}\) mice were crossed with gene-targeted mouse HL-deficient mice (hl\(^{-/-}\)) (32), and the resulting littersmates were bred to yield homozygosity for the gene-targeted mouse LDLR and HL genes and heterozygosity for the ciHL transgene (Ldlr\(^{-/-}\)/hl\(^{-/-}\)apob\(^{48/48}\)HL\(^{S145G}\)).

Background strains were identical within each genotype group, but differed between genotypes, so that Ldlr\(^{-/-}\)/apob\(^{48/48}\) background had 75% C57Bl/6 and 25% SJL, Ldlr\(^{-/-}\)/apob\(^{100/100}\) background had 81.25% C57Bl/6 and 18.75% SJL, and the Ldlr\(^{-/-}\)/hl\(^{-/-}\)/apob\(^{48/48}\) background had 96% C57/Bl6, 1.5% SJL, and 1.5% ICR.

Vector-specific expression of the HLS145G transgene was conferred by sequences in the HLA gene as described (6): 3 kb of the 5′-flanking sequence, the first exon, the first intron, and the first six untranslated nucleotides of the second exon, a poly linker for cDNA insertion, the nontranslated portion of the fourth exon, 0.1 kb of 3′-flanking sequence, and the first hepatic control region of the apoE locus.

MATERIALS AND METHODS

Expression of human ciHL

Plasma samples from mice fed a chow diet were collected in tubes containing ethylene diaminetetraacetic acid prior to and
10 min after tail vein injection of heparin (150 U/kg body weight) and were kept frozen at −80°C until analysis for protein expression. Western blot analysis of pre- and postheparin plasma was performed with a monospecific polyclonal rabbit antihuman HL antiserum (6).

Lipase assays
Triglyceride lipase activities were quantitated in two separate assays in triplicate with glycerol [1-14C]-trioleate-labeled triolein emulsion as a substrate in the presence of 1 M NaCl (35).

Lipoprotein analysis
Plasma was obtained by orbital vein bleeding after a 4 h fast. Mouse plasma lipoproteins were fractionated by fast-protein liquid chromatography (FPLC) on a Superose 6 HR 10/30 column (Amersham Pharmacia Biotech, Piscataway, NJ) as described previously (6). The cholesterol and triglyceride levels in whole plasma as well as in eluted fractions of plasma were determined with standard enzymatic assays (cholesterol: Abbot Spectrum, Abbott Park, IL; triglycerides: GPO-PAP kit, Boehringer Mannheim, Indianapolis, IN). The cholesterol and triglyceride concentrations in the eluted fractions (of plasma) were then corrected against the cholesterol and triglyceride concentrations in whole plasma to account for variability in the efficiency of the Superose 6 column (recovery). The recovery ranged from 70% to 100%.

Lipoprotein cholesterol and triglyceride concentrations were obtained by adding the concentrations of fractions 16–19 (VLDL), 20–22 (IDL), 23–27 (LDL), and 28–34 (HDL). Because cholesterol and triglyceride concentrations in the fractions (after correction for recovery) are calculated numbers, whereas plasma total cholesterol and triglycerides are actual measured numbers, only approximate comparisons can be made between total and lipoprotein lipids.

Western analysis of plasma apoE-48 and apoB-100
Plasmas from 4–5 mice of each genotype were pooled and subjected to Western blot analysis. The pooled plasmas were applied in quadruplicate or quintuplicate to 4% polyacrylamide–sodium dodecyl sulfate gels. Three to four individual gels were run (duplicate gels run for the Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> mice on a chow diet) to facilitate comparisons between genotypes and to ensure reproducibility. After blotting, nitrocellulose membranes were incubated with a rabbit anti-mouse apoB antibody that reacts with both apoB-48 and apoB-100 (34), incubated with biotinylated secondary antibody, and developed with an ECL kit (Amersham Pharmacia Biotech). Immunoblots were analyzed by densitometry on a GelDoc 2000 (Bio-Rad, Hercules, CA) using the Quantity One software package (Bio-Rad). Reproducibility of densitometry results was assessed by repeat measurements of individual blots.

Western analysis of plasma apoE and apoA-I
Plasma from 4–7 mice of each genotype were pooled, and the pooled plasmas were applied in quadruplicate or quintuplicate and fractionated on 12% polyacrylamide–sodium dodecyl sulfate gels (Bio-Rad) and transferred to nitrocellulose membranes. Three to four individual gels were run to facilitate comparisons between genotypes and to ensure reproducibility. The membranes were incubated with a goat anti-mouse apoE antibody (that also reacts with mouse apoA-I) (a gift from Dr. Karl H. Weisgraber, Gladstone Institute of Cardiovascular Disease), reacted with biotinylated second antibody, and analyzed as above.

Selective cholesteryl ester uptake assessment
The presence of a greater decrease in cholesterol than in apolipoprotein was used as an approximate measure of selective cholesteryl ester uptake. Thus, selective cholesteryl ester uptake was assumed to occur in VLDL, IDL, and LDL when lipoprotein cholesterol decreased to a greater extent than apoB-48 and/or apoB-100 levels. Likewise, HDL-selective cholesteryl ester uptake was assumed to occur when HDL-cholesterol (HDL-C) decreased but apoA-I levels remained virtually unchanged.

Diet study
To assess the dependence of the bridging function on lipoprotein lipid composition, six to nine animals of each of the Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> and Ldlr<sup>−/−</sup> apoB<sup>100/100</sup> and Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> and Ldlr<sup>−/−</sup> apoB<sup>100/100</sup>, and Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> and Ldlr<sup>−/−</sup> apoB<sup>100/100</sup> and apoB<sup>1−/−</sup>/apo<sup>B48/48</sup> mice were fed a cholesterol-enriched, high-fat (Western) diet (21% (w/w) fat and 0.15% (w/w) cholesterol) (TD 88137, Harlan, Teklad, Madison, WI) for 2 weeks. Fasted plasma lipoproteins were separated by FPLC, and plasma apolipoprotein levels were analyzed by Western blotting as described.

Statistical analysis
Data are presented as the mean ± SD. Student’s t-test for unequal variances was used to determine the statistical significance of differences.

RESULTS
Expression of the human ciHL transgene
PCR analysis for the ciHL transgene demonstrated a fragment of the expected 987 bp size in transgenic mice and its absence in nontransgenic mice. Western analysis of postheparin plasma confirmed the presence of the HL protein and demonstrated similar amounts of immunoreactive human HL in all transgenic mice (data not shown). The amounts of ciHL in postheparin plasma of all three genotypes were similar to the amounts of ciHL in the previously reported Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> and Ldlr<sup>−/−</sup> apoB<sup>100/100</sup> and Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> and apoB<sup>1−/−</sup>/apo<sup>B48/48</sup> mice. There was no human HL in the nontransgenic mice. Absence of human HL catalytic activity in postheparin plasma was verified by the lack of increased HL activity (above that of the endogenous mouse HL) in all genotypes (Table 1). Only background activity was present in the Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> and Ldlr<sup>−/−</sup> apoB<sup>100/100</sup> mice.

Plasma lipids and lipoproteins in Ldlr<sup>−/−</sup> apoB<sup>48/48</sup>, Ldlr<sup>−/−</sup> apoB<sup>100/100</sup>, and Ldlr<sup>−/−</sup> apoB<sup>1−/−</sup>/apo<sup>B48/48</sup> with and without ciHL on a chow diet
Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> background. Expression of ciHL reduced cholesterol levels by 25% in Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> HL<sup>Δ145G</sup> mice when compared with Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> mice [171 ± 4 mg/dl in Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> n = 4 vs 129 ± 27 mg/dl in Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> HL<sup>Δ145G</sup> mice n = 6, P < 0.02]. The triglyceride levels were not changed significantly (Table 2). Plasma lipoprotein profiles were determined by FPLC (Fig. 1). The FPLC cholesterol profiles in Ldlr<sup>−/−</sup> apoB<sup>48/48</sup> mice showed minimal elevations of VLDL and IDL and major peaks of LDL and HDL.
In ciHL-expressing mice, LDL-cholesterol (LDL-C) and HDL-C concentrations were reduced by 54% (46 ± 6 vs 19 ± 8 mg/dl, P < 0.002) and 21% (85 ± 8 vs 67 ± 16 mg/dl, P < 0.05), respectively (Fig. 1A and Table 2). The FPLC triglyceride profiles displayed a prominent peak in VLDL and moderate elevations in IDL and LDL. Expression of ciHL did not affect lipoprotein triglyceride levels significantly (Fig. 1D and Table 2).
levels by 18% in proteins. Thus, expression of ciHL reduced cholesterol

concentrations were reduced by 38% (61 vs 25 ± 33 mg/dl in Ldlr−/− apob100/100 HLS145G mice (n = 10) P < 0.003) (Table 2). The triglyceride levels were also decreased, although this decrease was not statistically significant (Table 2). The FPLC cholesterol profiles in Ldlr−/− apob100/100 mice showed a minimal elevation in VLDL, a prominent IDL/LDL peak, and a moderate elevation of HDL (Fig. 1B).

In ciHL-expressing mice, IDL-cholesterol (IDL-C) concentrations were reduced by 38% (61 ± 19 vs 38 ± 12 mg/dl, P < 0.003) (Fig. 1B and Table 2). There was also a trend toward reduction of LDL-C (Table 2). HDL-C levels were reduced by 30% (36 ± 6 vs 25 ± 7 mg/dl, P < 0.003) (Table 2).

The FPLC triglyceride profiles in Ldlr−/− apob100/100 mice displayed a small peak in VLDL and a prominent IDL/LDL peak (Fig. 1E). Expression of ciHL reduced triglyceride concentrations within the IDL subtraction by ~20% (Fig. 1E and Table 2).

Ldlr−/− hl−/− apob100/100 background. To eliminate endogenous murine HL activity as a confounding factor, we studied double knockout mice that were deficient in mouse HL and LDLR. Expression of ciHL reduced cholesterol by 24% in Ldlr−/− hl−/− apob100/100 HLS145G mice when compared with Ldlr−/− hl−/− apob100/100 mice [427 ± 60 mg/dl in Ldlr−/− hl−/− apob100/100 HLS145G mice (n = 9) vs 326 ± 38 mg/dl in Ldlr−/− hl−/− apob100/100 HLS145G mice (n = 6), P < 0.002]. The triglyceride levels were not changed significantly (Table 2). The FPLC cholesterol profiles in Ldlr−/− hl−/− apob100/100 mice demonstrated a moderate peak in VLDL, a prominent IDL/LDL peak, and a prominent HDL peak (Fig. 1C).

In ciHL-expressing mice, LDL-C concentrations were reduced by 30% (172 ± 38 vs 120 ± 23 mg/dl, P < 0.01) (Fig. 1F and Table 2). Remnant (IDL) and HDL-C concentrations were not reduced significantly.

The FPLC triglyceride profiles in Ldlr−/− hl−/− apob100/100 mice showed a marked peak in VLDL and a prominent IDL/LDL peak (Fig. 1F). Expression of ciHL did not affect lipoprotein triglyceride levels significantly (Fig. 1F and Table 2).

Plasma lipids and lipoproteins in Ldlr−/− apob100/100 and Ldlr−/− hl−/− apob100/100 mice with and without ciHL on a Western diet

Ldlr−/− apob100/100 background. The 2 week Western diet challenge increased plasma cholesterol substantially (3.5-

### Table 1. Plasma HL activities in male mice

| Lipase Activity & Lipoprotein | Ldlr−/− apob100/100 | Ldlr−/− apob100/100 | Ldlr−/− hls145G | Ldlr−/− hls145G |
|-------------------------------|---------------------|---------------------|----------------|----------------|
| Preheparin                    | 6 ± 1               | 7 ± 0               | 10 ± 1         | 7 ± 0          |
| Postheparin                   | 15 ± 0              | 19 ± 1              | 19 ± 1         | 17 ± 0         |

HL, hepatic lipase; LDLR, LDL receptor. 
* Lipase activities are expressed in μEq FFA per ml/h.

### Table 2. Plasma total and lipoprotein cholesterol and triglyceride concentrations on a chow diet

| Lipids | Ldlr−/− apob100/100 | Ldlr−/− apob100/100 | Ldlr−/− hls145G | Ldlr−/− hls145G |
|--------|---------------------|---------------------|----------------|----------------|
| TC     | 171 ± 4             | 120 ± 27           | 268 ± 42       | 235 ± 33       |
| TG     | 97 ± 57             | 78 ± 33            | 123 ± 30       | 102 ± 27       |
| VLDL-C | 7 ± 2               | 7 ± 4              | 9 ± 4          | 9 ± 2          |
| IDL-C  | 10 ± 2              | 7 ± 3              | 61 ± 19        | 38 ± 12        |
| LDL-C  | 46 ± 6              | 19 ± 8             | 148 ± 27       | 124 ± 31       |
| HDL-C  | 85 ± 8              | 67 ± 16            | 36 ± 6         | 25 ± 7         |
| VLDL-T | 34 ± 34             | 20 ± 8             | 23 ± 9         | 22 ± 9         |
| IDL-T  | 16 ± 14             | 10 ± 5             | 38 ± 15        | 30 ± 10        |
| LDL-T  | 25 ± 18             | 15 ± 9             | 57 ± 23        | 62 ± 25        |
| HDL-T  | 18 ± 12             | 16 ± 10            | 6 ± 4          | 4 ± 3          |

IDL-C, IDL-cholesterol; IDL-T, IDL-triglyceride; HDL-C, HDL-cholesterol; HDL-T, HDL-triglyceride; LDL-C, LDL-cholesterol; LDL-T, LDL-triglyceride; TC, plasma total cholesterol; TG, plasma total triglyceride; VLDL-T, VLDL-triglyceride. Plasma TC, TG, and lipoprotein and concentrations are in mg/dl. Values given as mean ± SD.

* P < 0.02 versus Ldlr−/− apob100/100 mice.

* P < 0.003 versus Ldlr−/− apob100/100 mice.

* P < 0.003 versus Ldlr−/− apob100/100 mice.

* P < 0.003 versus Ldlr−/− apob100/100 mice.

* P < 0.02 versus Ldlr−/− hl−/− apob100/100 mice.

* P < 0.01 versus Ldlr−/− hl−/− apob100/100 mice.
fold) in all mice on the Ldlr⁻/⁻ apob⁴⁸/⁴⁸ background. However, expression of ciHL reduced plasma cholesterol by 20% in Ldlr⁻/⁻ apob⁴⁸/⁴⁸ HLS¹⁴⁵G (n = 5) compared with Ldlr⁻/⁻ apob⁴⁸/⁴⁸ mice (1.019 ± 0.138 mg/dl vs 0.808 ± 0.186 mg/dl, P < 0.05) (Table 3). The triglyceride levels did not change significantly (Table 3).

Analysis of FPLC cholesterol profiles revealed a moderate VLDL peak, a large IDL/LDL peak, and a small HDL peak in Ldlr⁻/⁻ apob⁴⁸/⁴⁸ mice (Fig. 2A).

In ciHL-expressing mice, IDL-C concentrations were reduced by 28% (P < 0.04) (Fig. 2A and Table 3). The FPLC triglyceride profile revealed a moderate peak in VLDL only (Fig. 2B). Lipoprotein triglyceride levels did not change significantly in Ldlr⁻/⁻ apob¹⁰⁰/¹⁰⁰ HLS¹⁴⁵G mice (Fig. 2B and Table 3).

Surprisingly, expression of ciHL had no significant effect on plasma cholesterol levels. The triglyceride levels were not changed significantly. The FPLC cholesterol profiles revealed a sharp, prominent VLDL cholesterol peak and a prominent IDL/LDL-C peak (Fig. 2A and Table 3).
protein distribution significantly, but was associated with an increased concentration of HDL-C (Fig. 2C, D and Table 3). The FPLC triglyceride profile revealed a prominent VLDL peak. Expression of ciHL did not decrease the VLDL triglyceride peak. In fact, triglyceride levels were generally higher in the LDLr−/−/hl−/−/apoB−/− mice than in LDLr−/−/apoB−/− mice.

**Plasma apoB-48 and apoB-100 levels**

We next sought to estimate the respective contributions of whole-particle uptake (reflected by similar decreases in both cholesterol and apoB-48 or apoB-100) and selective cholesteryl ester uptake (reflected by a decrease in cholesterol but minimal or no decrease in apoB-48 or apoB-100) to the ciHL-mediated lipoprotein reduction. To do so, we assessed plasma apoB-48 and apoB-100 levels by densitometric scanning of Western blots (Table 4). The changes in apoB-48 and apoB-100 were then compared with the changes in lipoprotein cholesterol.

**Plasma apoB-48 and apoB-100 background.** Expression of ciHL reduced plasma apoB-48 levels by ~60% (P < 0.01) in chow-fed LDLr−/−/apoB−/−/HLS145G mice (in the presence of endogenous mouse HL). As expected, there was no apoB-100 in plasma from mice on the LDLr−/−/apoB−/−/apoB−/− genetic background (Table 4).

**Plasma apoB-48 and apoB-100 background.** Expression of ciHL reduced plasma apoB-100 by 27% (P < 0.03) in chow-fed LDLr−/−/apoB−/−/apoB−/−/HLS145G mice (in the presence of endogenous mouse HL) (Table 4). Interestingly, expression of ciHL did not reduce apoB-100 levels in Western diet-fed LDLr−/−/apoB−/−/apoB−/−/HLS145G mice (data not shown). [In fact apoB-100 levels were increased by ~16% (data not shown) despite a significant reduction in the HDL-C level (Table 3)]. As expected, there was no apoB-48 in plasma from mice on the LDLr−/−/apoB−/−/apoB−/− genetic background.

**Plasma apoB-48 and apoB-100 background.** Expression of ciHL reduced plasma apoB-48 levels by 14% (P < 0.01) in chow-fed LDLr−/−/apoB−/−/apoB−/−/HLS145G mice (in the absence of endogenous HL) but did not affect apoB-48 levels in Western diet-fed LDLr−/−/hl−/−/apoB−/−/HLS145G mice (Table 4). Plasma apoB-100 levels were not reduced significantly on either chow or Western diets in these mice (Table 4 and data not shown).

**Plasma apoE levels**

Next, using apoE as a marker of whole-particle uptake, we examined whether ciHL reduces cholesterol by mediating lipoprotein uptake.

**LDLr−/−/apoB−/−/apoB−/− background.** Expression of ciHL reduced plasma apoE levels (by ~30%, P < 0.005) in chow-fed LDLr−/−/apoB−/−/HLS145G mice (Table 4). However, this effect was lost when mice were fed a Western diet (data not shown).

**LDLr−/−/apoB−/−/apoB−/− background.** Expression of ciHL also reduced plasma apoE levels (by 14%, P < 0.03) in chow-fed LDLr−/−/apoB−/−/HLS145G mice (Table 4). However, this effect was lost when mice were fed a Western diet (data not shown).

**LDLr−/−/hl−/−/apoB−/−/apoB−/− background.** Likewise, expression of ciHL reduced plasma apoE levels (by 16%, P < 0.01) in chow-fed LDLr−/−/hl−/−/apoB−/−/apoB−/−/HLS145G mice (Table 4). However, this effect was lost when mice were fed a Western diet (data not shown).

**Plasma apoA-I levels**

To estimate whether the ciHL-mediated reduction in HDL-C occurred by whole-lipoprotein uptake (reflected by simultaneous reductions in cholesterol and apoA-I) or by selective cholesteryl ester uptake (reflected by reduction in cholesterol and minimal or no reduction in apoA-I), we assessed plasma apoA-I levels by densitometric scanning of Western blots.

**LDLr−/−/apoB−/−/apoB−/− background.** Expression of ciHL reduced plasma apoA-I by 40% in chow-fed LDLr−/−/apoB−/−/apoB−/− mice (Table 4).

**LDLr−/−/apoB−/−/apoB−/− background.** However, apoA-I was only slightly decreased in chow-fed LDLr−/−/apoB−/−/apoB−/−/HLS145G mice (Table 4). Western diet feeding did not reduce apoA-I levels in ciHL-expressing LDLr−/−/apoB−/−/apoB−/−/HLS145G mice (data not shown).
Likewise, apoA-I was only slightly decreased in chow-fed \( Ldlr^{-/-} \) mice (Table 4). Western diet feeding did not reduce apoA-I levels in ciHL-expressing \( Ldlr^{-/-} \) mice (data not shown).

### DISCUSSION

Our studies in genetically modified mice demonstrate that the bridging function of HL enhances uptake of both apoB-48- and apoB-100-containing lipoproteins and suggest that this occurs by several mechanisms, including whole-particle uptake and selective cholesteryl ester uptake. In addition, our studies indicate that the bridging function is modulated by diet and endogenous (murine) HL in these mouse models.

In LDLR-deficient apoB-48-only mice, LDL-sized lipoproteins and plasma apoB-48 were each reduced by ~50–60%. Thus, apoB-48-containing lipoproteins are indeed substrates for ciHL. These results are consistent with and extend previous studies in apoE-deficient mice, which have high levels of apoB-48 (6, 29). Overexpression of ciHL (either transgenically or by gene transfer) in those mice (Table 4).

### TABLE 4. Plasma apolipoprotein decrease in mice on a chow diet

| Apolipoprotein | \( Ldh^{-/-} \)apoB-48 | \( Ldh^{-/-} \)apoB100 apoB100/100 | \( Ldh^{-/-} \)apoB100 apoB100/100 | \( Ldh^{-/-} \)apoB100/100 HL5145G |
|----------------|-----------------------|------------------------------------|------------------------------------|---------------------------------|
| apoB-48        | 60$^a$                | ND                                 | 14$^d$                             |                                 |
| apoB-100       | ND                    | 27$^a$                             | 14                                 |                                 |
| apoE           | 30$^e$                | 14$^e$                             | 16$^e$                             |                                 |
| apoA1          | 40$^f$                | 2                                  | 10                                 |                                 |

Data are expressed as percent of nontransgenic mice (matched for genetic background). ND, not detected.

$^a$ \( P < 0.005 \) vs \( Ldh^{-/-} \)apoB48/48 mice.

$^b$ \( P < 0.01 \) vs \( Ldh^{-/-} \)apoB100/100 mice.

$^c$ \( P < 0.05 \) vs \( Ldh^{-/-} \)apoB100/100 mice.

$^d$ \( P < 0.01 \) vs \( Ldh^{-/-} \)apoB100/100 mice.

$^e$ \( P < 0.03 \) vs \( Ldh^{-/-} \)apoB100/100 mice.

$^f$ \( P < 0.01 \) vs \( Ldh^{-/-} \)apoB100/100 mice.
mice dramatically reduced levels of remnant- and LDL-sized lipoproteins (6, 29).

The similarly reductions in lipoprotein-cholesterol and apoB-48 suggest removal by whole-lipoprotein uptake. One mechanism by which ciHL mediates whole-lipoprotein uptake may involve (ciHL-mediated) contact between apoB-48-containing lipoproteins and the LDLR-related protein (LRP), which then removes the lipoprotein via endocytosis (36, 37). This mechanism is supported by a simultaneous decrease in plasma apoE (by ~30%, P < 0.005), (another ligand for the LRP), in the Ldlr−/−apoB100/100 HLD145G mice.

The LRP removes mainly apoB-48-containing lipoproteins (38). In several animal models, expression of receptor-associated protein (which inhibits LRP-mediated endocytosis) resulted in massive accumulation of apoB-48-containing lipoproteins (31, 39). The removal of apoB-48-containing lipoproteins via the LRP is mediated by apoE (37). Consistent with this, we demonstrated similar decreases in apoE and apoB-48 in both Ldlr−/−apoB100/100 HLD145G mice and Ldlr−/−hl−/−apoB100/100 HLD145G mice. Lipoprotein removal may also be enhanced by HSPG binding of lipoproteins (which serves both to concentrate them and to place them in proximity to receptors for uptake) (26, 40, 41). The HSPG-mediated removal mechanism of apoB-48-containing lipoproteins may include binding by apoE on the lipoprotein (37, 42). In addition to promoting receptor-mediated uptake, ciHL-mediated retention of lipoproteins at the cell surface likely facilitates selective cholesteryl ester uptake by the scavenger receptor BI (SR-BI) (43–46). Finally, an intriguing possibility is that cholesteryl depletion (via selective cholesteryl ester uptake) optimizes the particle for removal, thus accounting for the similar reductions in cholesterol and apoB-48 in Ldlr−/−apoB100/100 HLD145G mice.

A majority of apoB-100-containing lipoproteins are removed via the LDLR. However, in the course of experiments with apoB-100-only mice, we uncovered a ciHL-mediated mechanism for the removal of apoB-100-containing lipoproteins that is independent of the LDLR. Also, unlike the situation in LDLR-mediated whole-particle removal, the LDLR-independent, ciHL-mediated removal reduces cholesteryl to a greater extent than apoB-100. Potential mechanisms to explain why the ciHL-mediated cholesteryl reduction exceeds the apoB-100 reduction include preferential removal of larger, lipid-rich subclasses of lipoproteins (that have higher cholesteryl ester:apoB-100 ratios) and preferential removal of lipoproteins with a high cholesteryl ester:cholesterol ratio. These mechanisms would yield increased removal of cholesteryl ester relative to apoB-100. Although the apoB-100-containing particles also contain apoE, and therefore can be removed by the LRP pathway, the contribution of apoE to the removal is small in this animal model. Specifically, apoE decrease by 14% (on chow diet) or not at all (on Western diet), whereas IDL-C decreased by 37% (on chow diet) and by 20% (on Western diet) in ciHL-expressing Ldlr−/−apoB100/100 HLD145G mice.

An additional mechanism of LDLR-independent lipoprotein removal is by selective cholesteryl ester uptake. Selective cholesteryl ester uptake is suggested as one of the potential mechanisms here by findings in chow-fed Ldlr−/−apoB100/100 HLD145G mice, in which the combined reduction of remnant- and LDL-C (by 54%) was twice that of the reduction in plasma apoB-100 (reduced by 27%). Also, in Western diet-fed Ldlr−/−apoB100/100 HLD145G mice, IDL-C decreased by 20%, whereas apoB-100 remained virtually unchanged. It is suggested that the apoB-100-containing lipoproteins (bound to cell surface HSPG) are presented to the SR-BI for selective cholesteryl ester uptake. This is a reasonable possibility, because SR-BI binds both native and modified LDL and mediates selective cholesterol uptake from those lipoproteins (47). The cholesteryl-depleted particles may then be improved substrates for receptor-mediated or other uptake, thus explaining the reduced apolipoprotein levels.

Another explanation for the LDLR-independent lipoprotein removal is that ciHL-mediated retention of apoB-100-containing lipoproteins at the cell surface facilitates their removal by an HSPG-mediated pathway. This is supported by in vitro studies demonstrating that cells expressing either syndecan-1 (an HSPG core protein) or perlecan (a genetically distinct HSPG core protein) bound and internalized modified LDL (40, 41).

HDL-C levels were also reduced by ciHL, and this effect was modulated by endogenous mouse HL. In particular, ciHL expression in the presence of mouse HL reduced HDL-C levels in Ldlr−/−apoB100/100 HLD145G mice (by ~20%) and in Ldlr−/−apoB100/100 HLD145G mice (by ~30%). It is possible that the greater HDL-C reduction in Ldlr−/−apoB100/100 HLD145G mice reflects differences in particle affinity for ciHL; for instance, if apoB-48 has higher affinity for ciHL than apoB-100, there would be less CIH available to bind (and remove) HDL in apoB-48-only mice than in apoB-100-only mice.

Surprisingly, ciHL expression in the absence of mouse HL failed to significantly reduce HDL-C in Ldlr−/−hl−/−apoB100/100 HLD145G mice. These results suggest a role for polymeric modification (by endogenous mouse HL) in ciHL-mediated HDL removal. Interestingly, apoAI levels were reduced in Ldlr−/−apoB100/100 HLD145G mice (by 40%) but not in Ldlr−/−apoB100/100 HLD145G mice. Because HDL-C was reduced in both genetic backgrounds, these results indicate two different mechanisms for HDL removal for the two different genetic backgrounds, whole-particle uptake for the “apoB-48-only” mice and selective cholesterol uptake for the “apoB-100-only” mice.

We propose that cholesterol depletion of HDL by selective uptake may produce particles that are cleared more efficiently through other pathways (reflected by reductions in both HDL-C and apoAI). These in vivo results confirm in vitro findings in several cell lines, including McArdle7777 rat hepatoma cells and HOK 293 cells, of a 3-fold increase in 125I-labeled HDL uptake in the presence of ciHL, as compared with in its absence (28, 46). These results differ from the report of ciHL-mediated HDL reduction in (mouse) HL-deficient mice, in which high levels of ciHL were achieved by adenoviral-mediated gene
transfer (48). However, these differences may be explained by background strain differences or by the additional deficiency of the LDLR in our study.

Our results also demonstrate that endogenous mouse HL is not absolutely necessary for the effect of ciHL on apoB-containing lipoproteins. We observed a 30% reduction in LDL-C and also a trend toward reduction in remnants-sized lipoproteins in Ldlr<sup>-/-</sup>hk<sup>-/-</sup>apoB<sup>+/+</sup> HLS<sub>145G</sub> mice (in the absence of endogenous mouse HL activity) (Tables 2–4). Thus, catalytic modification was not required for ciHL-mediated removal of LDL-C in this genetic background. The LDL reduction observed in Ldlr<sup>-/-</sup>hk<sup>-/-</sup>apoB<sup>+/+</sup> HLS<sub>145G</sub> mice is compatible with human data in which LDL was not reduced in the presence of (reduced levels of) a naturally occurring mutant ciHL compared with in its absence (49). Although human HL deficiency is characterized by increased apoB-containing lipoproteins (and HDL) (and one might have expected reductions in these lipoproteins in the presence of ciHL compared with in its complete absence), the naturally occurring ciHL was reduced to one-fifth that of normal levels, which might explain the lack of an effect in these patients. Because in our study ciHL was increased (by ~20-fold) compared with normal levels, and because this increased ciHL reduced LDL, we conclude that ciHL-mediated LDL removal requires high levels of ciHL.

Our results demonstrate that the bridging function facilitates removal of both apoB-48- and apoB-100-containing lipoproteins and that their removal occurs by several different mechanisms. These mechanisms include whole-particle uptake and selective cholesteryl ester uptake. Also, our results show that the bridging function is modified by endogenous (murine) HL activity and diet.

This study was supported by National Institutes of Health Grant RO1 HL-69775 (H.L.D.) and the Gladstone Institutes. The authors thank Christine Yap, Thian-Poh Chong, and Jonathan Dinkins for excellent technical assistance.

REFERENCES

1. Jackson, R. L. 1983. Lipoprotein lipase and hepatic lipase. In The Enzymes. 3rd edition. Vol. 16. P. D. Boyer, editor. Academic Press, New York. 141–181.

2. Brunzell, J. D., and S. Deeb. 2001. Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency. In The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Vol. II. C. R. Scrivener, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. W. Kinzler, and B. Vogelstein, editors. McGraw-Hill Medical Publishing Company, 2789–2816.

3. Jansen, H., T. J. C. van Berkel, and W. C. Hülsmann. 1978. Binding of liver lipase to parenchymal and non-parenchymal rat liver cells. Biochem. Biophys. Res. Commun. 85: 148–152.

4. Sanan, S. A., J. Fan, A. Bensadoun, and J. M. Taylor. 1997. Hepatic lipase is abundant on both hepatocyte and endothelial cell surfaces in the liver. J. Lipid Res. 38: 1002–1013.

5. Breedveld, B., K. Schoonoverwoerd, A. J. M. Verhoeven, R. Willamsen, and H. Jansen. 1997. Hepatic lipase is localized at the parenchymal microvilli in rat liver. Biochem. J. 321: 425–430.

6. Dichek, D. L., W. Brecht, J. Fan, Z-S. Ji, S. P. A. McCormick, H. Akeefe, L. Conzo, D. A. Sanan, K. H. Weisgraber, S. G. Young, J. M. Taylor, and R. W. Mahley. 1998. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. J. Biol. Chem. 273: 1896–1903.

7. Shafi, S. S. E. Brady, A. Bensadoun, and R. J. Havel. 1994. Role of hepatic uptake in the intake and processing of chylomicron remnants in rat liver. J. Lipid Res. 35: 790–799.

8. Connelly, P. W. 1999. The role of hepatic lipase in lipoprotein metabolism. Clin. Chim. Acta. 286: 243–255.

9. Havel, R. J., and J. P. Kane. 2001. Structure and metabolism of plasma lipoproteins. In The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Vol. II. C. R. Scrivener, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. W. Kinzler, and B. Vogelstein, editors. McGraw-Hill, 2705–2716.

10. Kusui, T., P. Saarinne, and E. A. Nikkila. 1980. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein in man. Atherosclerosis, 36: 589–593.

11. Shirai, K., R. L. Barnhart, and R. L. Jackson. 1981. Hydrolysis of human plasma high density lipoprotein2-phospholipids and triglycerides by hepatic lipase. Biochem. Biophys. Res. Commun. 100: 591–599.

12. Breckenridge, W. C., J. A. Little, P. Alapovic, C. S. Wang, A. Kukis, G. Kakis, F. Lindgren, and G. Gardiner. 1982. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis, 45: 161–179.

13. Hegele, R. A., J. A. Little, C. Vezina, G. F. Maguire, L. Tu, T. S. Wolfever, D. J. A. Jenkins, and P. W. Connelly. 1993. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler. Thromb. 13: 720–728.

14. Auwerx, J., C. A. Marzetta, J. E. Hokanson, and J. D. Brunzell. 1998. Large brown fat LPL-like particles in hepatic lipase deficiency. Arterioscler. Thromb. 18: 319–325.

15. Brand, K. A. Dugi, J. D. Brunzell, D. N. Nevin, and S. Santamaria-Fojo. 1996. A novel A→G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. J. Lipid Res. 37: 1213–1223.

16. DeMan, T., J. S. J. T. 1999. The role of hepatic lipase in lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J. Clin. Invest. 70: 1184–1192.

17. Connelly, P. W., G. F. Maguire, M. Lee, and J. A. Little. 1990. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis, 10: 40–48.

18. Daggy, B. P., and A. Bensadoun. 1986. Enrichment of apolipoprotein B-48 in the LDL density class following in vivo inhibition of hepatic lipase. Biochem. Biophys. Acta. 877: 252–261.

19. Murase, T., and H. Iakura. 1981. Accumulation of intermediate density lipoprotein in plasma after intravenous administration of hepatic triglyceride lipase antibody in rats. Atherosclerosis, 39: 295–300.

20. Goldberg, I. J., N-A. Le, J. R. Paterniti, Jr., H. N. Ginsberg, F. T. Lindgren, and W. V. Brown. 1982. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J. Clin. Invest. 70: 1184–1192.

21. Fan, J., J. Wang, A. Bensadoun, S. J. Lauer, Q. Dang, R. W. Mahley, and J. M. Taylor. 1994. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc. Natl. Acad. Sci. USA. 91: 8724–8728.

22. Busch, S. J., R. L. Barnhart, G. A. Martin, M. C. Fitzgerald, M. T. Yates, S. T. T. Mao, C. E. Thomas, and R. L. Jackson. 1994. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J. Biol. Chem. 269: 16576–16582.

23. Applebaum-Bowden, D., J. Kobayashi, V. S. Kashyap, D. R. Brown, A. Berard, S. Meyn, C. Parrott, N. Maeda, R. Shamburek, H. B. Brewer, Jr., and S. Santamaria-Fojo. 1996. Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J. Clin. Invest. 97: 790–805.

24. Braschi, S., N. Couture, A. Gambarotta, B. R. Gauthier, C. R. Cofﬁll, D. L. Sparks, N. Maeda, and J. R. Schultz. 1996. Human hepatic lipase deficiency. In The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Vol. II. C. R. Scrivener, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. W. Kinzler, and B. Vogelstein, editors. McGraw-Hill Medical Publishing Company, 2789–2816.

25. Santamaria-Fojo, S., G. H. Dandelschiul, and M. Aam. 1998. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr. Opin. Lipidol. 9: 211–219.
Mahley. 1994. Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture. J. Biol. Chem. 269: 13429–13436.

27. Diard, P., M.-I. Malewicz, D. Lagrange, and S. Griglio. 1994. Hepatic lipase may act as a ligand in the uptake of artificial chylomicron remnant-like particles by isolated rat hepatocytes. Biochem. J. 299: 889–894.

28. Ji, Z.-S., H. L. Dichek, R. D. Miranda, and R. W. Mahley. 1997. Heparan sulfate proteoglycans participate in hepatic lipase- and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J. Biol. Chem. 272: 31283–31292.

29. Amar, M. J., K. A. Dugi, C. C. Haudenschild, R. D. Shamburek, B. Foger, M. Chase, A. Bensadoun, R. F. Hoyt, H. B. Brewer, and S. Santamarina-Fojo. 1998. Hepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoE-deficient mice. J. Lipid Res. 39: 2436–2442.

30. Dichek, H. L., S. M. Johnson, H. Akeefe, G. T. Lo, E. Sage, C. E. Yap, and R. W. Mahley. 2001. Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice. J. Lipid Res. 42: 201–210.

31. Véniant, M., C. Zlot, R. Walzem, V. Pierotti, R. Driscoll, D. Dichek, J. Herz, and S. G. Young. 1998. Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J. Clin. Invest. 102: 1559–1568.

32. Homanics, G. E., H. V. de Silva, J. Osada, S. H. Zhang, H. Wong, J. Borenzstajn, and N. Maeda. 1995. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J. Biol. Chem. 270: 2974–2980.

33. Gaw, A., F. P. Mancini, and S. Ishibashi. 1995. Rapid genotyping of and apolipoprotein E. J. Lipid Res. 36: 249–249.

34. McCormick, S. P. A., J. K. Ng, M. Véniant, J. Borén, V. Pierotti, L. M. Flynn, D. S. Grass, A. Connolly, and S. G. Young. 1996. Transgenic mice that overexpress mouse apolipoprotein B gene are distant from the structural gene. J. Biol. Chem. 271: 11963–11970.

35. Iverius, P.-H., and J. D. Brunzell. 1985. Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. Am. J. Physiol. 249: E107–E114.

36. Cooper, A. D. 1997. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38: 2173–2192.

37. Mahley, R. W., and Z. S. Ji. 1999. Remnant lipoprotein metabolism. Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40: 1–16.

38. Rohlmann, A., M. Gotthardt, R. E. Hammer, and J. Herz. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101: 689–695.

39. Willnow, T. E., Z. Sheng, S. Ishibashi, and J. Herz. 1994. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 254: 1471–1474.

40. Fuki, I. V., K. M. Kuhn, I. R. Lomazov, V. L. Rothman, G. P. Tuszynski, R. V. Iozzo, T. L. Swenson, E. A. Fisher, and K. J. Williams. 1997. The syndecan family of proteoglycans: novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100: 1611–1622.

41. Fuki, I. V., R. V. Iozzo, and K. J. Williams. 2000. Perlec an heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. J. Biol. Chem. 25742–25750.

42. Ji, Z.-S., W. J. Brecht, R. D. Miranda, M. M. Hussain, T. L. Innerarity, and R. W. Mahley. 1995. Role of hepatic sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268: 10160–10167.

43. Acton, S., A. Rigotti, K. T. Landschulz, S. Xu, H. H. Hobbs, and M. Krieger. 1996. Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor. Science. 271: 518–520.

44. Steinberg, D. 1996. A docking receptor for HDL cholesterol esters. Science. 271: 460–461.

45. Wang, N., W. Weng, J. L. Breslow, and A. R. Tall. 1996. Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J. Biol. Chem. 271: 21001–21004.

46. Lambert, G., M. B. Chase, K. Dugi, A. Bensadoun, H. B. Brewer, Jr., and S. Santamarina-Fojo. 1999. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor BI. J. Lipid Res. 40: 1294–1303.

47. Acton, S. L., P. E. Scherer, H. F. Lodish, and M. Krieger. 1994. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269: 21003–21009.

48. Dugi, K. A., M. J. A. Amar, C. C. Haudenschild, R. D. Shamburek, A. Bensadoun, R. F. Hoyt, Jr., J. Fruchart-Najib, Z. Madj, H. B. Brewer, Jr., and S. Santamarina-Fojo. 2000. In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. Arterioscler. Thromb. Vasc. Biol. 20: 793–800.

49. Zambon, A., S. S. Deeb, A. Bensadoun, K. Foster, and J. D. Brunzell. 2000. In vivo evidence of a role for hepatic lipase in human apolipoprotein metabolism, independent of its catalytic activity. J. Lipid Res. 41: 2094–2099.